ArticleAvicenna journal of phytomedicine
The hydroalcoholic extract of
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Nasturtium officinale (N. officinale (NO)) has been widely used in traditional medicine. This study investigates the protective effects of NO against hepatic and renal damage induced by CCl Materials and Methods: Male Wistar rats were divided into two arms: A (CCl4-induced hepatotoxicity) and B (gentamicin-induced nephrotoxicity). Seventeen groups were formed by dividing arms A and B, with nine groups in arm A and eight groups in arm B (n=5). Rats were daily treated with various doses (50, 100, and 200 mg/kg BW) of N. officinale extract (NOE) (Total extract; Oral gavage) for 14 and 28 days in arm A and B, respectively. Biochemical and histopathological evaluations and gene expression analyses were conducted on blood, liver, and kidney tissues. Results: NOE treatment significantly modulated B-cell lymphoma protein 2 (Bcl-2)-associated X (Bax) and B-cell lymphoma protein 2 (Bcl-2) expression in kidney tissue, reducing Bax (p<0.01) and increasing Bcl-2 (p<0.05). In liver tissue, NOE inhibited tumor necrosis factor alpha (TNF-α) (p<0.01) and Interleukin-1 beta (IL-1β) (p<0.001), while reducing AST and ALT activity (p<0.001). Additionally, blood urea nitrogen (BUN) levels significantly decreased (p<0.05) in nephrotoxic rats. Conclusion: Our findings highlight the capability of NOE as a promising therapeutic against liver and kidney damage induced by CCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.